CDKN1A and breast carcinoma: Kometiani et al. reported cell cycle arrest of breast cancer cells after their treatment with compound 1 (concentrations were far below the half-maximal inhibitory concentration [IC50]), which was caused by activation of the SrcK pathway and subsequently increased levels of the cell cycle inhibitor p21cip1 (cyclin-dependent kinase inhibitor 1) [114].